Virus therapy tested for Tough-to-Treat ovarian cancer
NCT ID NCT06618235
Summary
This early-stage trial is testing a new virus-based therapy called THEO-260 for women with advanced ovarian cancer that has stopped responding to standard platinum chemotherapy. The main goals are to find the safest and most effective dose and to see if the treatment shows signs of fighting the cancer. Participants receive six doses over two weeks and are closely monitored for side effects and treatment response.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Imperial College Healthcare NHS Trust, Hammersmith Hospital
RECRUITINGLondon, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Oxford University Hospitals NHS Foundation Trust, Churchill Hospital
RECRUITINGOxford, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Beatson West of Scotland Cancer Centre
RECRUITINGGlasgow, Scotland, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.